|Composition : ||1mg/ml,2mg/2ml|
|Indications : ||Acute leukemia, lymphomas, Hodgkin's disease, non-Hodgkin lymphosarcoma, neuroblastoma, rhabdomyosarcoma, Wilm's tumour.|
|Contraindications :||Pregnancy, lactation, demyelinating form of Charcot Marie tooth disease.|
|Safety Profile : ||The needle should be properly placed in the vein. If leakage occurs in surrounding tissues, considerable irritation will occur. Local injection of hyaluronidase & moderate heat will minimize the discomfort. Used only by iv route. Considerable irritation can occur if extravasated into surrounding tissue.|
|Adverse Effects : ||Hair loss, leucopenia, neuritic pain, constipation, sensory loss, paraesthesia, difficulty in walking, loss of deep tendon reflexes, muscle wasting, fever, hypersensitivity reaction, weight loss, polyuria, urinary retention, hypertension, cranial nerve palsies, headache, bone pains, jaw pain, parotid pain, myalgia, convulsions, syndrome of inappropriate secretion of ADH.|
|Drug Interactions : ||If given with phenytoin, there is increased seizure activity. Acute bronchospasm with mitomycin-C.|
|Dosage : ||Given iv at weekly intervals.|
Children : 2mg/m² (if <10kg, start with 0.05mg/kg/week).
Adult : 1.4 mg/m².
Decrease the dose to 50%, if S. bilirubin is >3mg/dl. Not given to patient getting radiation thereby through ports that include liver.
|Purity :||Not less than 99%.|